Publications of Albert Beckers
Bookmark and Share    
Full Text
See detailLe syndrome de Klinefelter : actualités cliniques et thérapeutiques
VALDES SOCIN, Hernan Gonzalo ULiege; Rey, R; COPPENS, Luc ULiege et al

in Vaisseaux, Coeur, Poumons (in press), 24(1),

Detailed reference viewed: 26 (5 ULiège)
Full Text
See detailExcellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
Coopmans, Eva C.; van Meyel, Sebastiaan W. F.; Pieterman, Kay J. et al

in European journal of endocrinology (2019)

Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very ... [more ▼]

Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without temozolomide. Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy , a second-generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis, or both was observed after PAS-LAR administration suggesting an antitumor effect. This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis, or both in prolactinomas. [less ▲]

See detailHow do they grow so tall
Beckers, Albert ULiege

Scientific conference (2019, May 09)

See detailWhat is new in Familial Isolated Pituitary Adenomas
BECKERS, Albert ULiege

Scientific conference (2019, March 29)

Detailed reference viewed: 11 (0 ULiège)
Full Text
See detailAIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center.
Daly, Adrian ULiege; Cano, David A.; Venegas, Eva et al

in Endocrine Connections (2019)

BACKGROUND: Pituitary adenomas have a high disease burden due to tumor growth/invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset ... [more ▼]

BACKGROUND: Pituitary adenomas have a high disease burden due to tumor growth/invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be resistant to medical therapy. AIMS: We performed a retrospective screening study using published risk criteria to assess the frequency of AIP and MEN1 mutations in pituitary adenoma patients in a tertiary-referral center. METHODS: Pituitary adenoma patients with pediatric/adolescent onset, macroadenomas occurring </=30 years of age, familial isolated pituitary adenoma (FIPA) kindreds, and acromegaly or prolactinoma cases that were uncontrolled by medical therapy were studied genetically. We also assessed whether immunohistochemical staining for AIP (AIP-IHC) in somatotropinomas was associated with somatostatin analogs (SSA) response. RESULTS: Fifty-five patients met the study criteria and underwent genetic screening for AIP/MEN1 mutations. No mutations were identified and large deletions/duplications were ruled out using MLPA. In a cohort of sporadic somatotropinomas, low AIP-IHC tumors were significantly larger (p=0.002) and were more frequently sparsely-granulated (p=0.046) than high AIP-IHC tumors. No significant relationship between AIP-IHC and SSA responses was seen. CONCLUSIONS: Germline mutations in AIP/MEN1 in pituitary adenoma patients are rare and the use of published risk criteria did not identify cases in a large tertiary-referral setting. In acromegaly, low AIP-IHC was related to larger tumor size and more frequent sparsely-granulated subtype but no relationship with SSA-responsiveness was seen. The genetics of aggressive, treatment-resistant and familial pituitary adenomas remain largely unexplained and screening criteria could be significantly refined. [less ▲]

Detailed reference viewed: 20 (3 ULiège)
See detailEndocrine rare diseases
Beckers, Albert ULiege

Scientific conference (2019, February 19)

Detailed reference viewed: 14 (0 ULiège)
See detailPituitary tumourigenesis - What's new
Beckers, Albert ULiege

Scientific conference (2019, February 15)

Detailed reference viewed: 13 (0 ULiège)
Full Text
See detailEpidemiology and Management Challenges in Prolactinomas.
VROONEN, Laurent ULiege; Daly, Adrian ULiege; Beckers, Albert ULiege

in Neuroendocrinology (2019)

Clinically relevant pituitary adenomas are present in about 1 per 1000 of the general population and prolactinomas are by far the most common clinical subtype of pituitary adenomas. Usually prolactinomas ... [more ▼]

Clinically relevant pituitary adenomas are present in about 1 per 1000 of the general population and prolactinomas are by far the most common clinical subtype of pituitary adenomas. Usually prolactinomas affect pre-menopausal women and present with typical symptoms of menstrual disturbance and/or galactorrhea. They are generally managed with dopamine agonists to restore fertility and to control symptoms and tumour size. In a subset of prolactinomas, however, management remains challenging. Studies in recent years have identified the factors related to dopamine agonist resistance, such as, male sex, genetic features, and aggressive tumor behaviour. Certain other patient groups represent particular challenges for management, such as pediatric patients and pregnant women. Treatment with dopamine agonists is usually safe and effective, and adverse effects such as clinically relevant cardiac valvular complications and impulse control disorders may occur in isolated instances. A number of important disease characteristics of prolactinomas remain to be explained, such as the difference in sex prevalence before and after menopause, the higher prevalence of macroadenomas in older males and the biochemical mechanisms of resistance to dopaminergic agonists. [less ▲]

Detailed reference viewed: 26 (6 ULiège)
See detailLe secret des Géants
Beckers, Albert ULiege

Scientific conference (2019, January 18)

Detailed reference viewed: 13 (0 ULiège)
Full Text
See detailGenetic Testing in Pituitary Adenomas: What, How, and In Whom?
Daly, Adrian ULiege; Beckers, Albert ULiege

in Endocrinología, Diabetes y Nutrición (2019), 66(2), 71-73

Detailed reference viewed: 35 (7 ULiège)
Full Text
See detailIntérêt de la génétique dans l'exploration du gigantisme hypophysaire
PETIGNOT, Sandrine ULiege; ROSTOMYAN, Liliya ULiege; Beckers, Albert ULiege

in Vaisseaux, Coeur, Poumons (2019), 24(2), 21-28

Detailed reference viewed: 28 (6 ULiège)
See detailHow do they grow so tall. Genetics of gigantism
Beckers, Albert ULiege

Scientific conference (2018, December)

Detailed reference viewed: 11 (0 ULiège)
Full Text
See detailThyroid dysfunction after Alemtuzumab treatment for multiple sclerosis : a report of four cases
Daniel, Sara ULiege; HANSEN, Isabelle ULiege; Dive, Dominique ULiege et al

in Acta Clinica Belgica (2018, December), 73(2),

Detailed reference viewed: 92 (8 ULiège)
See detailElements du diagnostic initial de l'acromegale. Données d'une base internationale
Beckers, Albert ULiege

Scientific conference (2018, November 23)

Detailed reference viewed: 14 (0 ULiège)
See detailGigantism
Beckers, Albert ULiege

Scientific conference (2018, November)

Detailed reference viewed: 19 (2 ULiège)
See detailFamilial Pituitary Tumors - Updates in Pituitary tumor diagnosis and management
Beckers, Albert ULiege

Scientific conference (2018, November)

Detailed reference viewed: 10 (0 ULiège)
Full Text
See detailDiagnostic de l'acromégalie : observations à partir d'une base de données internationales
Beckers, Albert ULiege; PETROSSIANS, Patrick ULiege

in Mises au point clinique d'Endocrinologie, nutrition et métabolisme 2018 (2018)

Detailed reference viewed: 35 (6 ULiège)
Full Text
See detailThe causes and consequences of pituitary gigantism
Beckers, Albert ULiege; PETROSSIANS, Patrick ULiege; Hanson, Julien ULiege et al

in Nature Reviews. Endocrinology (2018), 14

In the general population, height is determined by a complex interplay between genetic and environmental factors. Pituitary gigantism is a rare but very important subgroup of patients with excessive ... [more ▼]

In the general population, height is determined by a complex interplay between genetic and environmental factors. Pituitary gigantism is a rare but very important subgroup of patients with excessive height, as it has an identifiable and clinically treatable cause. The disease is caused by chronic growth hormone and insulin-like growth factor 1 secretion from a pituitary somatotrope adenoma that forms before the closure of the epiphyses. If not controlled effectively, this hormonal hypersecretion could lead to extremely elevated final adult height. The past 10 years have seen marked advances in the understanding of pituitary gigantism, including the identification of genetic causes in \~50\% of cases, such as mutations in the AIP gene or chromosome Xq26.3 duplications in X-linked acrogigantism syndrome. Pituitary gigantism has a male preponderance, and patients usually have large pituitary adenomas. The large tumour size, together with the young age of patients and frequent resistance to medical therapy, makes the management of pituitary gigantism complex. Early diagnosis and rapid referral for effective therapy appear to improve outcomes in patients with pituitary gigantism; therefore, a high level of clinical suspicion and efficient use of diagnostic resources is key to controlling overgrowth and preventing patients from reaching very elevated final adult heights. [less ▲]

Detailed reference viewed: 44 (17 ULiège)